 |
|
Nonmyeloablative Hematopoietic Stem Cell Transplantation for Systemic Lupus Erythematosus
Richard K. Burt, MD;
Ann Traynor, MD;
Laisvyde Statkute, MD;
Walter G. Barr, MD;
Robert Rosa, MD;
James Schroeder, MD;
Larissa Verda, MD, PhD;
Nela Krosnjar, MD;
Kathleen Quigley, RN;
Kimberly Yaung, RN;
Marcello Villa, BS;
Miyuki Takahashi, MD;
Borko Jovanovic, PhD;
Yu Oyama, MD
JAMA. 2006;295:527-535.
Context Manifestations of systemic lupus erythematosus (SLE) may in most patients be ameliorated with medications that suppress the immune system. Nevertheless, there remains a subset of SLE patients for whom current strategies are insufficient to control disease.
Objective To assess the safety of intense immunosuppression and autologous hematopoietic stem cell support in patients with severe and treatment-refractory SLE.
Design, Setting, and Participants A single-arm trial of 50 patients with SLE refractory to standard immunosuppressive therapies and either organ- or life-threatening visceral involvement. Patients were enrolled from April 1997 through January 2005 in an autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT) study at a single US medical center.
Interventions Peripheral blood stem cells were mobilized with cyclophosphamide (2.0 g/m2) and granulocyte colony-stimulating factor (5 µg/kg per day), enriched ex vivo by CD34+ immunoselection, cryopreserved, and reinfused after treatment with cyclophosphamide (200 mg/kg) and equine antithymocyte globulin (90 mg/kg).
Main Outcome Measures The primary end point was survival, both overall and disease-free. Secondary end points included SLE Disease Activity Index (SLEDAI), serology (antinuclear antibody [ANA] and anti–double-stranded (ds) DNA), complement C3 and C4, and changes in renal and pulmonary organ function assessed before treatment and at 6 months, 12 months, and then yearly for 5 years.
Results Fifty patients were enrolled and underwent stem cell mobilization. Two patients died after mobilization, one from disseminated mucormycosis and another from active lupus after postponing the transplantation for 4 months. Forty-eight patients underwent nonmyeloablative HSCT. Treatment-related mortality was 2% (1/50). By intention to treat, treatment-related mortality was 4% (2/50). With a mean follow-up of 29 months (range, 6 months to 7.5 years) for patients undergoing HSCT, overall 5-year survival was 84%, and probability of disease-free survival at 5 years following HSCT was 50%. Secondary analysis demonstrated stabilization of renal function and significant improvement in SLEDAI score, ANA, anti-ds DNA, complement, and carbon monoxide diffusion lung capacity adjusted for hemoglobin.
Conclusions In treatment-refractory SLE, autologous nonmyeloablative HSCT results in amelioration of disease activity, improvement in serologic markers, and either stabilization or reversal of organ dysfunction. These data are nonrandomized and thus preliminary, providing the foundation and justification for a definitive randomized trial.
Clinical Trial Registration ClinicalTrials.gov Identifier: NCT00271934
Author Affiliations: Division of Immunotherapy (Drs Burt, Traynor, Statkute, Verda, Krosnjar, Takahashi, and Oyama, Mss Quigley and Yaung, and Mr Villa), Division of Rheumatology (Drs Barr and Schroeder), Division of Nephrology (Dr Rosa), and Department of Preventive Medicine (Dr Jonanovic), Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill. Dr Traynor is now with the Division of Hematology/Oncology, University of Massachusetts, Worcester.
RELATED ARTICLE
High-Dose Cyclophosphamide and Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus
Michelle Petri and Robert Brodsky
JAMA. 2006;295(5):559-560.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Complete Remission of Psoriasis After Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
Braiteh et al.
JCO 2008;26:4511-4513.
FULL TEXT
Resolution of SLE-related soft-tissue calcification following haematopoietic stem cell transplantation
Mandelbrot et al.
Nephrol Dial Transplant 2008;23:2679-2684.
ABSTRACT
| FULL TEXT
Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis
Larghero et al.
Ann Rheum Dis 2008;67:443-449.
ABSTRACT
| FULL TEXT
Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases
Burt et al.
JAMA 2008;299:925-936.
ABSTRACT
| FULL TEXT
Correction of Celiac Disease After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia
Kline et al.
Pediatrics 2007;120:e1120-e1122.
ABSTRACT
| FULL TEXT
Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells
Smith-Berdan et al.
Blood 2007;110:1370-1378.
ABSTRACT
| FULL TEXT
Review: Lupus in adolescence
Kone-Paut et al.
Lupus 2007;16:606-612.
ABSTRACT
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus
Voltarelli et al.
JAMA 2007;297:1568-1576.
ABSTRACT
| FULL TEXT
Cellular Therapy for Type 1 Diabetes: Has the Time Come?
Skyler
JAMA 2007;297:1599-1600.
FULL TEXT
Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used
Loh et al.
Blood 2007;109:2643-2548.
ABSTRACT
| FULL TEXT
What's new in the other general journals
Tonks
BMJ 2006;332:351-352.
FULL TEXT
High-Dose Cyclophosphamide and Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus
Petri and Brodsky
JAMA 2006;295:559-560.
FULL TEXT
|
